Deubiquitinase USP45 stabilizes RTCB and DDX1, promoting tumorigenesis and chemoresistance
- Int J Biol Macromol. 2025 Dec 28;339(Pt 2):149970. doi: 10.1016/j.ijbiomac.2025.149970.
- 1. Key Laboratory of Bio-Resource and Eco-environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, Sichuan, 610065, China.
- 2. Medical Innovation Center, Sichuan University of Science & Engineering, Zigong, Sichuan, 643000, China.
- 3. State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610075, China. Electronic address: [email protected].
- 4. Key Laboratory of Bio-Resource and Eco-environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, Sichuan, 610065, China. Electronic address: [email protected].
- 5. Key Laboratory of Bio-Resource and Eco-environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, Sichuan, 610065, China; SeNA Research Institute, School of Life Sciences, Hubei University, Wuhan, Hubei, 430062, China. Electronic address: [email protected].
The RNA Ligase RTCB and DEAD-box helicase DDX1 regulate critical processes including MicroRNA maturation and DNA repair, with emerging roles in tumorigenesis and chemoresistance. However, their post-translational regulatory mechanisms remain elusive. Here, we identify the Deubiquitinase USP45 as a central coordinator that interacts and co-localizes with RTCB and DDX1. USP45 directly removes polyubiquitin chains from both proteins, thereby stabilizing RTCB and DDX1 in a substrate-specific manner. Notably, USP45-mediated DDX1 deubiquitination requires RTCB, whereas RTCB deubiquitination is DDX1-independent, revealing an asymmetric regulatory hierarchy. Functionally, USP45 cooperates with RTCB and DDX1 to regulate tumor-associated phenotypes in both cellular and murine models, including promoting cell proliferation through RTCB-dependent DDX1 deubiquitination and enhancing chemoresistance through both RTCB- and DDX1-driven pathways. Clinical bioinformatics analyses further reveal that elevated expression of USP45, RTCB, and DDX1 correlates with poor patient survival. Our findings establish the USP45-RTCB-DDX1 axis as a dual driver of oncogenesis and chemoresistance via specific RTCB/DDX1 post-translational stabilization, nominating USP45 inhibition as a therapeutic strategy to suppress Cancer progression and overcome treatment resistance.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: Topoisomerase; ADC Payloads; AMPK; Autophagy; Apoptosis; HIV; HBV; Mitophagy; Antibiotic; Bacterial; Fluorescent Dye
-
Cat. No.Product NameCategory/Application